Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer.
Purity:
99.0%
CAS Number:
[1629760-28-6]
Target:
Others
* VAT and and shipping costs not included. Errors and price changes excepted